Previous 10 | Next 10 |
Alcon (NYSE: ALC ): Q1 Non-GAAP EPS of $0.45 beats by $0.11 ; GAAP EPS of -$0.12 misses by $0.02 . Revenue of $1.84B (+1.1% Y/Y) beats by $150M . Press Release More news on: Alcon Inc., Earnings news and commentary, Healthcare stocks news,
Solid first quarter sales of $1.8 billion, an increase of 3%, or 4% constant currency Successful launch of PATADAY strengthens Alcon's leadership in the US OTC allergy market Decline in global demand for surgical procedures will negatively impact second quarter resul...
Alcon (NYSE: ALC ) is scheduled to announce Q1 earnings results on Tuesday, May 12th, after market close. The consensus EPS Estimate is $0.34 and the consensus Revenue Estimate is $1.69B (-5.1% Y/Y). Over the last 1 year, ALC has beaten EPS estimates 25% of the time and has beat...
Clinical benefits of AcrySof ® IQ PanOptix ® Trifocal IOL for patients and NGENUITY ® 3D Visualization System for surgeons to be presented Data to show the now widely available ARGOS ® Biometer with Image Guidance as a differentiated cataract planning option ...
Source : ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Read more ...
In this episode of Industry Focus: Wildcard , Jason Moser and Motley Fool contributor Brian Feroldi give a breakdown of three great small caps you probably didn't know about. They range from a service provider to a surgical company and finally a research and consultancy firm. Find out wh...
New York City, NY: April 06, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Cataract Surgery Treatments Market in Global Industry: 2020 Research and New Innovations in Medical Devices Sector. The prime objective of the report is to offer upd...
This article is first in a series that provides an ongoing analysis of the changes made to Wedgewood Partners’ 13F stock portfolio on a quarterly basis. It is based on David Rolfe’s regulatory 13F Form filed on 02/14/2020. The 13F portfolio value decreased ~13%, from $1.13B to ...
This article is part of a series that provides an ongoing analysis of the changes made to Tweedy Browne's 13F portfolio on a quarterly basis. It is based on Tweedy Browne's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking Tweedy Browne Portfolio series to get an idea of t...
Vivity complements Alcon’s existing IOL portfolio by providing an additional option for cataract patients to treat presbyopia A first-of-its-kind, non-diffractive lens that offers a continuous extended range of vision while maintaining a low incidence of visual disturbances, ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior ...
2024-06-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...